🔬 The company offers fermentation lines with a capacity of up to 650 liters for mRNA and protein production.
💪 The expansion will create additional development and production capabilities for advanced therapy medicinal products.
🧪 New laboratories will support bioprocess development for pDNA, mRNA, and recombinant proteins.
🔬 This expansion complements Wacker Biotech US’s nucleic acid expertise and supports research and preclinical development.
Introduction:
Wacker Biotech US, a subsidiary of Wacker Chemie based in San Diego, is expanding its mRNA and protein production capabilities. The company offers fermentation lines with a capacity of up to 650 liters, allowing for the production and purification of pDNA, pharmaceutical proteins, and mRNA. Wacker Biotech US is now creating additional development and production capacities to serve the U.S. market in the field of advanced therapy medicinal products.
- Wacker Biotech US is expanding its bioprocess development capabilities for pDNA, mRNA, and recombinant proteins to support research and preclinical development.
- The expansion includes the creation of new laboratories to enhance nucleic acid expertise and complement existing services.
- The company benefits from the expertise of the global Wacker Biotech team and is strategically located in a biotech hub in San Diego.
Conclusion:
Wacker Biotech US is investing in expanding its production capacity in San Diego to meet the growing demand for mRNA and protein production. The additional development and production capacities will support research and preclinical development in the field of advanced therapy medicinal products. This expansion highlights the company’s commitment to providing high-quality bioprocess development services to the U.S. market.
